Terri Febbraro1, Ernst Lengyel1, Iris L Romero2. 1. Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA. 2. Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA. Electronic address: iromero@uchicago.edu.
Abstract
OBJECTIVE: There is increasing pre-clinical and clinical evidence that metformin, a commonly used diabetes medication, has a protective effect in cancer. The aim of this review is to discuss metformin's anti-cancer molecular mechanisms of action and to summarize the current literature demonstrating metformin's potential in gynecologic cancer prevention and treatment. METHODS: A PubMed search was conducted combining the keywords "metformin" with "neoplasm", "uterine neoplasms", "ovarian neoplasms", and "uterine cervical neoplasms". Studies published in English between 1994 and 2014 were included. RESULTS: Pre-clinical studies in endometrial, ovarian, and cervical cancer suggest that metformin inhibits the growth of cancer cells. The primary molecular mechanism mediating this effect appears to be the activation of AMP-activated protein kinase (AMPK) and the subsequent inhibition of mammalian targets of rapamycin (mTOR). The pre-clinical findings are augmented by clinical studies indicating that metformin use is associated with a reduced risk of cancer and improved survival in diabetic women with ovarian and endometrial cancers. No clinical analyses have evaluated metformin use and cervical cancer. Overall, the data showing a favorable effect of metformin is strongest for endometrial and ovarian cancer and prospective clinical testing is ongoing in these two malignancies. CONCLUSIONS: Numerous clinical studies have reported an association between metformin use by diabetic patients and improved outcomes in gynecologic cancers. In addition, pre-clinical reports have identified plausible biological mechanisms to explain the molecular mechanism of action of metformin in cancer. However, the most important question remains unanswered: Will metformin be effective against cancer in patients without diabetes? Until this question is answered with prospective clinical testing, the role of metformin in the treatment or prevention of gynecologic malignancies remains theoretical and the clinical use of metformin as a cancer therapeutic is experimental.
OBJECTIVE: There is increasing pre-clinical and clinical evidence that metformin, a commonly used diabetes medication, has a protective effect in cancer. The aim of this review is to discuss metformin's anti-cancer molecular mechanisms of action and to summarize the current literature demonstrating metformin's potential in gynecologic cancer prevention and treatment. METHODS: A PubMed search was conducted combining the keywords "metformin" with "neoplasm", "uterine neoplasms", "ovarian neoplasms", and "uterine cervical neoplasms". Studies published in English between 1994 and 2014 were included. RESULTS: Pre-clinical studies in endometrial, ovarian, and cervical cancer suggest that metformin inhibits the growth of cancer cells. The primary molecular mechanism mediating this effect appears to be the activation of AMP-activated protein kinase (AMPK) and the subsequent inhibition of mammalian targets of rapamycin (mTOR). The pre-clinical findings are augmented by clinical studies indicating that metformin use is associated with a reduced risk of cancer and improved survival in diabeticwomen with ovarian and endometrial cancers. No clinical analyses have evaluated metformin use and cervical cancer. Overall, the data showing a favorable effect of metformin is strongest for endometrial and ovarian cancer and prospective clinical testing is ongoing in these two malignancies. CONCLUSIONS: Numerous clinical studies have reported an association between metformin use by diabeticpatients and improved outcomes in gynecologic cancers. In addition, pre-clinical reports have identified plausible biological mechanisms to explain the molecular mechanism of action of metformin in cancer. However, the most important question remains unanswered: Will metformin be effective against cancer in patients without diabetes? Until this question is answered with prospective clinical testing, the role of metformin in the treatment or prevention of gynecologic malignancies remains theoretical and the clinical use of metformin as a cancer therapeutic is experimental.
Authors: Reuben J Shaw; Katja A Lamia; Debbie Vasquez; Seung-Hoi Koo; Nabeel Bardeesy; Ronald A Depinho; Marc Montminy; Lewis C Cantley Journal: Science Date: 2005-11-24 Impact factor: 47.728
Authors: G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng Journal: J Natl Cancer Inst Date: 2000-06-07 Impact factor: 13.506
Authors: G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: Peter C Hart; Tatsuyuki Chiyoda; Xiaojing Liu; Melanie Weigert; Marion Curtis; Chun-Yi Chiang; Rachel Loth; Ricardo Lastra; Stephanie M McGregor; Jason W Locasale; Ernst Lengyel; Iris L Romero Journal: Mol Cancer Res Date: 2019-01-17 Impact factor: 5.852
Authors: Amanda de Barros Machado; Vania Dos Reis; Sebastian Weber; Julia Jauckus; Ilma Simoni Brum; Helena von Eye Corleta; Thomas Strowitzki; Edison Capp; Ariane Germeyer Journal: Oncol Lett Date: 2016-08-23 Impact factor: 2.967
Authors: Teresa Peart; Yudith Ramos Valdes; Rohann J M Correa; Elena Fazio; Monique Bertrand; Jacob McGee; Michel Préfontaine; Akira Sugimoto; Gabriel E DiMattia; Trevor G Shepherd Journal: Oncotarget Date: 2015-09-08